Key result
Synbiotic supplementation reduces total cholesterol, LDL-C, and systolic BP vs placebo at 12 weeks.
Why the study?
Lipid abnormalities and hypertension are prevalent in kidney transplant recipients, prompting assessment of the impact of synbiotic supplementation on serum lipids, lipoproteins, and blood pressure in those with overweight or obesity.
Does synbiotic supplementation reduce serum lipid levels, lipoproteins, and blood pressure in kidney transplant recipients with overweight or obesity compared with placebo?
RCT (n=46)
placebo-controlled
random allocation
Does synbiotic supplementation reduce serum lipid levels, lipoproteins, and blood pressure in kidney transplant recipients with overweight or obesity compared with placebo?
A 12-week course of daily synbiotic supplementation significantly lowered total cholesterol, LDL-cholesterol, and systolic blood pressure compared with placebo in overweight or obese kidney transplant recipients.
Answers are grounded in this paper and cite their sources.
Supports adjunctive synbiotics for lipids and systolic BP in overweight kidney transplant recipients; extends RCT evidence to this high-risk population.
Lipid abnormalities and hypertension are prevalent in kidney transplant (KT) recipients. This research aimed to assess the impact of synbiotic supplementation on serum lipid levels, lipoproteins and blood pressure among KT recipients with overweight or obesity. In this randomised controlled trial, forty-six KT recipients were allocated randomly to either the synbiotic group or the placebo group. Those in the synbiotic group received two capsules containing synbiotics daily for a duration of 12 weeks, whereas the placebo group was given an equivalent placebo. Serum levels of total cholesterol, TAG, LDL-cholesterol, HDL-cholesterol and lipoprotein (a) [Lp(a)], along with systolic and diastolic blood pressure were measured. The results indicated significant reductions in serum total cholesterol ( P = 0·022; effect size= −0·75), LDL-cholesterol ( P = 0·037; effect size: −0·68) and systolic blood pressure ( P = 0·034; effect size: −0·74) in the synbiotic group compared with the placebo group. Additionally, serum TAG ( P = 0·048; effect size: −0·44) and diastolic blood pressure ( P = 0·001; effect size: −1·04) showed significant decreases by week 12 relative to baseline measurements within the synbiotic group. However, there were no significant changes in serum HDL-cholesterol and Lp(a) for either group throughout the study period. Overall, this study indicated that synbiotic supplementation reduces total serum cholesterol, LDL-cholesterol, TAG and both systolic and diastolic blood pressure in KT recipients.
No takes yet. Share an insight, caveat, or question.
Karimi et al. (2026) conducted an RCT in Kidney transplant recipients with overweight or obesity (n=46). Synbiotic supplementation vs. Equivalent placebo was evaluated on Serum total cholesterol, LDL-cholesterol, and systolic blood pressure (effect size -0.75 (total cholesterol), -0.68 (LDL-C), -0.74 (SBP), p=0.022 (total cholesterol), 0.037 (LDL-C), 0.034 (SBP)). Synbiotic supplementation reduced total cholesterol, LDL-C, and systolic BP vs placebo at 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: